FDA Awaits GAO Report To Guide Behind-The-Counter Policy
This article was originally published in The Tan Sheet
Executive Summary
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs
You may also be interested in...
Behind The Counter Debate Raises Questions Of Pharmacist Role In Diagnosis
A behind-the-counter class of drugs would inevitably put pharmacists in the position of diagnosing patients' conditions, opponents say
Behind The Counter Debate Raises Questions Of Pharmacist Role In Diagnosis
A behind-the-counter class of drugs would inevitably put pharmacists in the position of diagnosing patients' conditions, opponents say
Behind The Counter Debate Raises Questions Of Pharmacist Role In Diagnosis
A behind-the-counter class of drugs would inevitably put pharmacists in the position of diagnosing patients' conditions, opponents say